BioPharma Dive January 8, 2026
With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in the last two years.
Radiopharmaceutical drug developer Aktis Oncology on Thursday said it raised $318 million from an initial public offering, the first for a biotechnology company in 2026.
Aktis priced 17.65 million shares at $18 each, more than what it planned to sell, according to an updated securities filing earlier this week. It upsized the round after Eli Lilly, which previously partnered with the cancer drugmaker, stepped in to purchase $100 million, or a third of the shares. Aktis will begin trading Friday on the Nasdaq under the ticker symbol “AKTS.”
The company, which is based in Boston, is developing a...
Today's Sponsors
Today's Sponsor